154. Li,Z.B., Cai,W., Cao,Q., Chen,K., Wu,Z., He,L. and Chen,X. (2007) (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J. Nucl. Med., 48, 1162–1171. 155. Temming,K., Lacombe,M., van der Hoeven,P., Prakash,J., Gonzalo,T., Dijkers,E.C., Orﬁ,L., Keri,G., Poelstra,K., Molema,G. et al. (2006) Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology. Bioconjug. Chem., 17, 1246–1255. 156. Aderem,A. and Underhill,D.M. (1999) Mechanisms of phagocy- tosis in macrophages. Annu. Rev. Immunol., 17, 593–623. 157. Underhill,D.M. and Ozinsky,A. (2002) Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol., 20, 825–852. 158. van Vlerken,L.E., Vyas,T.K. and Amiji,M.M. (2007) Poly(ethylene glycol)-modiﬁed nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res., 24, 1405–1414. 159. Amantana,A., Moulton,H.M., Cate,M.L., Reddy,M.T., Whitehead,T., Hassinger,J.N., Youngblood,D.S. and Iversen,P.L. (2007) Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem., 18, 1325–1331. 160. Wolfrum,C., Shi,S., Jayaprakash,K.N., Jayaraman,M., Wang,G., Pandey,R.K., Rajeev,K.G., Nakayama,T., Charrise,K., Ndungo,E.M. et al. (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol., 25, 1149–1157. 161. Duxbury,M.S., Ashley,S.W. and Whang,E.E. (2005) RNA inter- ference: a mammalian SID-1 homologue enhances siRNA uptake and gene silencing eﬃcacy in human cells. Biochem. Biophys. Res. Commun., 331, 459–463. 162. Tsang,S.Y., Moore,J.C., Huizen,R.V., Chan,C.W. and Li,R.A. (2007) Ectopic expression of systemic RNA interference defective protein in embryonic stem cells. Biochem. Biophys. Res. Commun., 357, 480–486. 163. Moschos,S.A., Jones,S.W., Perry,M.M., Williams,A.E., Erjefalt,J.S., Turner,J.J., Barnes,P.J., Sproat,B.S., Gait,M.J. and Lindsay,M.A. (2007) Lung delivery studies using siRNA con- jugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem., 18, 1450–1459. 164. Nishina,K., Unno,T., Uno,Y., Kubodera,T., Kanouchi,T., Mizusawa,H. and Yokota,T. (2008) Eﬃcient in vivo delivery of Nucleic Acids Research, 2008, Vol. 36, No. 12 4171 siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther., 16, 734–740. 165. Hu-Lieskovan,S., Heidel,J.D., Bartlett,D.W., Davis,M.E. and Triche,T.J. (2005) Sequence-speciﬁc knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res., 65, 8984–8992. 166. Heidel,J.D., Yu,Z., Liu,J.Y., Rele,S.M., Liang,Y., Zeidan,R.K., Kornbrust,D.J. and Davis,M.E. (2007) Administration in non- human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA, 104, 5715–5721. 167. Li,S.D., Chen,Y.C., Hackett,M.J. and Huang,L. (2008) Tumor- targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther., 16, 163–169. 168. Peer,D., Park,E.J., Morishita,Y., Carman,C.V. and Shimaoka,M. (2008) Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inﬂammatory target. Science, 319, 627–630. 169. Zimmermann,T.S., Lee,A.C., Akinc,A., Bramlage,B., Bumcrot,D., Fedoruk,M.N., Harborth,J., Heyes,J.A., Jeﬀs,L.B., John,M. et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature, 441, 111–114. 170. Sato,Y., Murase,K., Kato,J., Kobune,M., Sato,T., Kawano,Y., Takimoto,R., Takada,K., Miyanishi,K., Matsunaga,T. et al. (2008) Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-speciﬁc chaperone. Nat. Biotechnol., 26, 431–442. 171. Szoka,F. (2008) Molecular biology. The art of assembly. Science, 319, 578–579. 172. Luten,J., van Nostrum,C.F., De Smedt,S.C. and Hennink,W.E. (2008) Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Control Release, 126, 97–110. 173. Satija,J., Gupta,U. and Jain,N.K. (2007) Pharmaceutical and biomedical potential of surface engineered dendrimers. Crit. Rev. Ther. Drug Carrier Syst., 24, 257–306. 174. Petros,R.A., Ropp,P.A. and DeSimone,J.M. (2008) Reductively labile PRINT particles for the delivery of doxorubicin to HeLa cells. J. Am. Chem. Soc., 130, 5008–5009. 175. Allen,T.M. and Martin,F.J. (2004) Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol., 31, 5–15. 176. Kirpotin,D.B., Drummond,D.C., Shao,Y., Shalaby,M.R., Hong,K., Nielsen,U.B., Marks,J.D., Benz,C.C. and Park,J.W. (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internali- zation in animal models. Cancer Res., 66, 6732–6740.